Panmure Gordon reaffirmed their buy rating on shares of Venture Life Group PLC (LON:VLG) in a research report sent to investors on Monday morning. Panmure Gordon currently has a GBX 128 ($1.58) price objective on the stock.

Separately, Beaufort Securities restated a speculative buy rating on shares of Venture Life Group PLC in a report on Monday, August 1st.

Venture Life Group PLC (LON:VLG) opened at 54.00 on Monday. Venture Life Group PLC has a one year low of GBX 43.00 and a one year high of GBX 81.92. The company’s 50-day moving average is GBX 51.57 and its 200 day moving average is GBX 55.79. The stock’s market capitalization is GBX 19.89 million.

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Stock Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related stocks with our FREE daily email newsletter.